company background image

BiomX NYSEAM:PHGE Stock Report

Last Price


Market Cap







30 Sep, 2022


Company Financials +
PHGE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health5/6

PHGE Stock Overview

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.

BiomX Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BiomX
Historical stock prices
Current Share PriceUS$0.34
52 Week HighUS$3.12
52 Week LowUS$0.30
1 Month Change-38.18%
3 Month Change-51.46%
1 Year Change-88.82%
3 Year Change-96.63%
5 Year Changen/a
Change since IPO-96.48%

Recent News & Updates

Shareholder Returns

PHGEUS BiotechsUS Market

Return vs Industry: PHGE underperformed the US Biotechs industry which returned -25.8% over the past year.

Return vs Market: PHGE underperformed the US Market which returned -21.5% over the past year.

Price Volatility

Is PHGE's price volatile compared to industry and market?
PHGE volatility
PHGE Average Weekly Movement15.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: PHGE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: PHGE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2015111Jonathan Solomon

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials.

BiomX Fundamentals Summary

How do BiomX's earnings and revenue compare to its market cap?
PHGE fundamental statistics
Market CapUS$10.19m
Earnings (TTM)-US$36.14m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHGE income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$36.14m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.21
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio44.8%

How did PHGE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is PHGE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHGE?

Other financial metrics that can be useful for relative valuation.

PHGE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does PHGE's PB Ratio compare to its peers?

PHGE PB Ratio vs Peers
The above table shows the PB ratio for PHGE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.2x
ALLR Allarity Therapeutics
BBLG Bone Biologics
PTIX Protagenic Therapeutics
DFFN Diffusion Pharmaceuticals

Price-To-Book vs Peers: PHGE is good value based on its Price-To-Book Ratio (0.3x) compared to the peer average (1.2x).

Price to Earnings Ratio vs Industry

How does PHGE's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: PHGE is good value based on its Price-To-Book Ratio (0.3x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is PHGE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHGE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PHGE's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of PHGE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PHGE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PHGE's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is BiomX forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHGE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PHGE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PHGE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PHGE is forecast to have no revenue next year.

High Growth Revenue: PHGE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHGE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has BiomX performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PHGE is currently unprofitable.

Growing Profit Margin: PHGE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: PHGE is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.

Accelerating Growth: Unable to compare PHGE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: PHGE has a negative Return on Equity (-110.39%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is BiomX's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PHGE's short term assets ($48.3M) exceed its short term liabilities ($6.5M).

Long Term Liabilities: PHGE's short term assets ($48.3M) exceed its long term liabilities ($19.2M).

Debt to Equity History and Analysis

Debt Level: PHGE has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PHGE's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PHGE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PHGE has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 30% each year.

Discover healthy companies


What is BiomX current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

BiomX Dividend Yield vs Market
How does BiomX dividend yield compare to the market?
SegmentDividend Yield
Company (BiomX)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (BiomX)n/a

Notable Dividend: Unable to evaluate PHGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PHGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PHGE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHGE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PHGE has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Jonathan Solomon (45 yo)





Mr. Jonathan Eitan Solomon, MBA, serves as Chief Executive Officer at BiomX Ltd since May 2017 and Director since October 2019. Mr. Solomon co-founded ProClara (formerly NeuroPhage Pharmaceuticals, Inc.) i...

CEO Compensation Analysis

Jonathan Solomon's Compensation vs BiomX Earnings
How has Jonathan Solomon's remuneration changed compared to BiomX's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$1mUS$391k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$1mUS$339k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$937kUS$286k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$605kUS$276k


Dec 31 2017US$566kUS$266k


Compensation vs Market: Jonathan's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD772.00K).

Compensation vs Earnings: Jonathan's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: PHGE's management team is considered experienced (2.8 years average tenure).

Board Members

Experienced Board: PHGE's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHGE?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders693,0882.3%
Private Companies3,637,84612.1%
VC/PE Firms4,946,89116.5%
General Public17,839,94059.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.4%.

Top Shareholders

Top 25 shareholders own 40.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Symbiosis LLC
3,637,846$1.2m0%no data
OrbiMed Advisors LLC
Johnson & Johnson Innovation - JJDC, Inc.
Takeda Ventures, Inc.
MM Asset Management Inc
Jonas Sven Grossman
372,717$126.7k0%no data
Royce & Associates, LP
328,655$111.7k2.49%no data
Gbolahan Amusa Benz
262,871$89.4k0%no data
Millennium Management LLC
78,933$26.8k-18.92%no data
Bridgeway Capital Management, LLC
58,700$20.0k0%no data
Meitav Investment House Ltd
55,346$18.8k-4.82%no data
The Phoenix Investment and Finances Ltd.
45,259$15.4k-1.22%no data
Renaissance Technologies LLC
42,200$14.3k76.57%no data
Jonathan Solomon
25,000$8.5k0%no data
Migdal Mutual Funds Ltd.
23,336$7.9k0%no data
Jane Street Group, LLC, Asset Management Arm
22,462$7.6k-10.09%no data
Psagot Index Funds Ltd
13,477$4.6k0%no data
Lynne Sullivan
12,500$4.3k0%no data
Paul Sekhri
12,500$4.3k0%no data
UBS Asset Management
10,608$3.6k631.59%no data
Harel Mutual Funds Ltd.
8,340$2.8k0%no data
BlackRock, Inc.
5,750$2.0k0%no data
Marina Wolfson
3,750$1.3k0%no data
Russell Greig
3,750$1.3k0%no data
Psagot Mutual Funds Ltd.
3,012$1.0k0%no data

Company Information

BiomX Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: BiomX Inc.
  • Ticker: PHGE
  • Exchange: NYSEAM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$10.192m
  • Shares outstanding: 29.98m
  • Website:

Number of Employees


  • BiomX Inc.
  • 22 Einstein Street
  • Floor 5
  • Ness Ziona
  • 7414003
  • Israel


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHGETASE (The Tel-Aviv Stock Exchange)YesCommon StockILILSMar 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.